Navigation Links
NW Bio 2012 Annual Report Shows Strong Progress And Enhancement Of Leadership Position
Date:4/8/2013

>

"2012 was a watershed year for NW Bio.  Years of work quietly building our key programs reached critical mass," commented Linda F. Powers, CEO of NW Bio. "Our strong progress on so many fronts in 2012 has positioned us for further acceleration in 2013, and sharpened our leadership position in the immune therapy space."

Progress in Lead Program:  Clinical Trial With DCVax-L for Brain CancerDuring 2012, the Company's ongoing trial with DCVax-L for Glioblastoma multiforme (GBM) brain cancer was upgraded to Phase III trial status in the US, and was also approved in the UK to proceed as a Phase III trial.  The trial was expanded from 240 patients to 312 patients, and significant enhancements of the trial (including additional interim analyses) were added.  The trial expanded from 25 US sites at year end 2011, to 42 sites operating in the US and nearly 30 sites selected and in varying stages in Europe at year end 2012.

In the UK, the Company launched its partnering with Kings College Hospital and Kings College London -- premiere opinion-leader institutions.  Three other premiere sites were also selected and agreed to participate in the trial, including Queens Hospital in Birmingham, University College Hospital in London, and Addenbroke Hospital in Cambridge.

In Germany, 24 hospital centers across the country were selected and agreed to participate in the trial.  The Company's partnership with the Fraunhofer Institute was expanded.  A $5.5 million grant was awarded by the German government (one of the largest such grants ever awarded), providing matching funds for up to half of the Company's trial costs and manufacturing costs there, which the Company plans to start drawing upon in Q2 of 2013.  In the fall, 10 leading hospital centers across Germany, including all of the key opinion leaders in brain cancer, applied to the German healthcare system for authorization of reimbursement for DCVax-L for GBM br
'/>"/>

SOURCE Northwest Biotherapeutics
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. DIA 2013 49th Annual Meeting to Address Hot Topics Surrounding Patient Therapies
2. Rosetta Genomics Announces Poster Presentations at AACR Annual Meeting 2013
3. Susan Cain Will Kick Off 2013 ASAE Annual Meeting & Exposition, Dan Heath is Closing General Session Speaker
4. Electronic Headband That Detects and Treats Addictive In-Sleep Behavior to be Demonstrated at Annual Holistic Dental Conference by Holistic Technologies
5. Professional Pricing Society Explores New Role of Pricers as Change Agents and Leaders at 24th Annual Spring Conference
6. Upsher-Smith Presents Favorable Phase I Data For USL261, A Novel Formulation Of Intranasal Midazolam, At 65th Annual Meeting Of The American Academy Of Neurology
7. NW Bio To Review Its Leadership Position In Immune Therapy At The 25th Annual Roth Conference
8. Smith & Nephew hosts thought-leading surgeons, showcases new technology at American Academy of Orthopaedic Surgeons annual meeting
9. Archimedes Inc. Renews Annual Marketing Agreement with HealthEconomics.Com
10. Palatin Technologies To Present At The 25th Annual ROTH Conference
11. Keryx Biopharmaceuticals to Present at the 25th Annual ROTH Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... SPRINGS, Florida , September 19, 2014 ... companies release latest developments, patents and results of studies ... GNSZ), Eli Lilly and Company (NYSE: LLY ... Celgene Corporation (NASDAQ: CELG ) and Arena ... GNSZ), a leader in developing prodrug therapeutics for the ...
(Date:9/19/2014)... 2014 , The first grants ... Paediatric Endocrinology (ESPE) Meeting  Investment supports innovative ... in the field of growth  , EMD ... Germany , today announced the first recipients of ... awards were announced during a Satellite Symposium organized by ...
(Date:9/18/2014)... LONDON , Sept. 18, 2014 ... near-patient testing, is performed outside a clinical laboratory. ... hence in administrating appropriate treatments and medication. POCT ... and prevalence of lifestyle diseases such as diabetes, ... and user-friendly. POCT devices are standardized to minimize ...
(Date:9/18/2014)... DUBLIN, Ireland , September 18, ... ,Research and Markets ( http://www.researchandmarkets.com/research/czvg3s/biocompatible ) ... "Biocompatible Materials - Global Strategic ... offering. ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) ,This report ... Materials in US$ Million by the ...
Breaking Biology Technology:Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 2Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 3Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 4Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 5Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 6Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 7EMD Serono Awards Grant for Growth Innovation (GGI) for the First Time 2EMD Serono Awards Grant for Growth Innovation (GGI) for the First Time 3POCT Market in China 2014-2018 2Biocompatible Materials - Global Strategic Business Report 2014 2Biocompatible Materials - Global Strategic Business Report 2014 3
... , , CLEVELAND, Sept. 9 ... for ways to drive out costs and inefficiencies. Because it,s proven ... documents that go along with them, many are turning to enterprise ... the roadblock: budgets are tighter than ever, so how do these ...
... , , THE WOODLANDS, Texas, Sept. ... LXRX ), a biopharmaceutical company focused on discovering and developing breakthrough treatments ... Ph.D. , Lexicon,s president and chief executive officer, will present at ... in New York, New York on Tuesday, September 15, 2009 at 1:35 ...
... BRIDGEWATER, England, September 9 Clinical Therapeutics,(, http://www.clinicaltherapeutics.com/ ... announce the addition of Michael G. Spigarelli, MD, ... As section editor for the Pediatric, ... the,Pediatric Research section), Dr. Spigarelli brings a wealth ...
Cached Biology Technology:Hyland Software Provides Grant Assistance to Kick-Start Technology Projects 2Hyland Software Provides Grant Assistance to Kick-Start Technology Projects 3Hyland Software Provides Grant Assistance to Kick-Start Technology Projects 4Lexicon Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Unplugged Conference 2Clinical Therapeutics Announces the Addition of Michael G. Spigarelli, MD, PhD, as Editor for a Refocused Pediatric, Adolescent, & Maternal Therapeutics Section 2
(Date:9/19/2014)... species which over thousands of years has adapted to the ... that makes the cold dangerous for you. , This is ... and the cold provoking substance, called nonylphenol, comes from the ... suspected of being a endocrine disruptor, but when entering the ... ability to protect the cells in its body from cold ...
(Date:9/18/2014)... Boulder, Colo., USA A new GSA Bulletin ... along the lower Rio Puerco and Chaco Wash in ... tree rings from salt cedar and willow, investigators were ... thick or greater. They then combined this data with ... reconstruct the history of these arroyos. , Arroyos are ...
(Date:9/18/2014)... A novel robotic system that can operate inside the ... as part of a biomedical research partnership program at ... of determining if the robot, in conjunction with real-time ... accurate, less costly, and less discomforting for the patient. ... prostate cancer therapies with greater precision. , Developed by ...
Breaking Biology News(10 mins):Environmental pollutants make worms susceptible to cold 2Environmental pollutants make worms susceptible to cold 3Tree rings and arroyos 2Tree rings and arroyos 3Tree rings and arroyos 4Tree rings and arroyos 5Tree rings and arroyos 6Tree rings and arroyos 7Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 2Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 3Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 4Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 5
... the Sundarbans, resulting in as much as 200m of coast ... (11th Jan) in Remote Sensing by scientists from ... development thrives, and global temperature continues to rise, natural protection ... rates. This will inevitably lead to species loss in this ...
... W. Finberg, MD, the Richard M. Haidack Professor of ... University of Massachusetts Medical School, is lead investigator on ... predicting how the influenza virus changes and evolves in ... This approach has promise for becoming a pivotal tool ...
... cells can be grown on biocompatible scaffolds to form ... repair and regeneration of damaged or diseased tissue. However, ... a specific pattern or alignment. An innovative method for ... tissue architectures is described in an article in ...
Cached Biology News:Bengali forests are fading away 2
...
Human Presenilin-2 NTF Affinity Purified Polyclonal Ab...
2'-Fluorine-CTP (2'-F-CTP) is readily incorporated into transcripts by T7 and SP6 R&DNA™ Polymerase and is available separately....
Human Glypican 2 Biotinylated Affinity Purified PAb...
Biology Products: